This is a parallel arm, pilot study used to examine the feasibility of electronic patient reported outcome measures (ePROMs) for symptom assessment and monitoring as well as a linked self-management support and decision support information hub (https://symptomcare.org) to facilitate symptom management for patients on maintenance hemodialysis.

Two dialysis centers will be included in the study, with one center receiving SUPPORT-Dialysis (intervention arm) and the other receiving standard care (control arm).

In Canada, 20,000-25,000 patients with end-stage kidney disease (ESKD) experience a range of symptoms such as chronic pain, itchiness, fatigue, anxiety, depression and sleep disturbances [1-5]. These may impact quality of life, increase mortality, decrease treatment adherence, and increased hospitalizations [6-8]. These symptoms are under-managed and under-recognized among these patients, but screening and managing symptoms using patient reported outcomes measures (PROMs) may be a useful and inexpensive solution. PROMS have previously been used successfully in cancer care [8-9], and have potential for clinical care of patients with kidney failure as well.

Electronic collection of PROMs (ePROMs) facilitates PROMs use by allowing linkage to electronic patient records [10-11] and immediate scoring and presentation of results to patients and clinicians [12-14]. ePROMs allow the use of computer adaptive testing (CAT) to personalize questions, increase the precision of measurements and reduce survey burden [15-17]. The investigators also developed a self-management support and decision support resource hub(https://symptomcare.org) to help dialysis patients and their clinical team in identifying and managing relevant physical and psychological symptoms that require further assessment and potential intervention.

Patients will complete Patient Reported Outcome Measurement Information System (PROMIS) CAT surveys on an electronic data capture system (SUPPORT-Dialysis) every four weeks during their dialysis treatment for six months. In the intervention, patients with moderate/severe symptoms will be flagged for the clinical team. Moderate/severe symptoms will be determined based on whether the participants score above a pre-defined cut-off in the surveys. The participant, primary nurse, and nephrologist will also receive an output report and be given access to https://symptomcare.org for suggested symptom management actions.

To establish the feasibility and acceptability of the intervention, the investigators will assess

1. Recruitment Rate
2. Retention and Completion rate
3. Acceptability
4. Patient satisfaction
5. Staff satisfaction

Based on the objectives of this study, the investigators hypothesize the following:

1. Recruitment goals will be met; >50% of approached patients will consent; completion rate will be > 80% of participants at least 50% of the time, and dropout rate will be < 30%.
2. >80% of patients find the toolkit acceptable; <20% of staff find the process intrusive to workflow.

Inclusion Criteria:

• Patients undergoing maintenance hemodialysis for more than 3 months

Exclusion Criteria:

• Patients with severe acute illness or condition that hampers questionnaire completion assessed by clinical team.
• Dementia indicated in the medical record, indicated by the managing healthcare team.
• Unable to understand English - as assessed by clinical team.
• Life expectancy < 6 months as assessed by main responsible nephrologist.
• Unwilling or unable to provide informed consent.

Individual participant data that underlie the results reported in publications, after deidentification (text, tables, figures, and appendices).

Beginning 9 months and ending 36 months following article publication.

Researchers who provide a methodologically sound purpose to achieve aims in the approved proposal or for individual participant data meta-analysis. Proposals should be directed to istvan.mucsi@uhn.ca. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website.